Organization | NantWorks

NantWorks Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: San Diego CA United States (2002)

Status: Acquired by ImmunityBio, Inc. (2020)

Organization Overview

First Clinical Trial

2006

NCT00646230

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NantBioScience, Inc. | NantKwest, Inc. | Nant Operations Center

Active Ingredients

Drugs in Phase 3 Trials (4)

Key: NantWorks (0) Acquired (4)

alt-803 (20 trials)

bacille calmette-guerin (2 trials)

ganitumab (12 trials)

gemcitabine (gemzar) (8 trials)

Drugs in Phase 2 Trials (53)

Key: NantWorks (0) Acquired (53)

aahi-sc2 (1 trial)

ad-cea vaccine (1 trial)

aldoxorubicin (11 trials)

alpelisib (Piqray) (1 trial)

alt-801 (6 trials)

alt-836 (2 trials)

amg-337 (2 trials)

atezolizumab (Tecentriq) (2 trials)

autologous mononuclear stem cell (1 trial)

autologous natural killer cells (1 trial)

avelumab (bavencio) (15 trials)

bevacizumab (avastin) (9 trials)

capecitabine (xeloda) (10 trials)

carboplatin (paraplatin) (3 trials)

cetuximab (erbitux) (4 trials)

cisplatin (platinol) (7 trials)

conatumumab (3 trials)

cyclophosphamide (cytoxan) (16 trials)

docetaxel (taxotere) (1 trial)

doxorubicin (Doxil) (1 trial)

elotuzumab (empliciti) (1 trial)

ensituximab (2 trials)

etoposide (vepesid) (1 trial)

exemestane (aromasin) (1 trial)

fluorouracil (efudex) (15 trials)

fulvestrant (faslodex) (3 trials)

gi-4000 (12 trials)

gi-6207 (8 trials)

gi-6301 (11 trials)

had5-s-fusion+n-etsd vaccine (5 trials)

hank (1 trial)

irinotecan (Camptosar) (2 trials)

leucovorin (14 trials)

melphalan (alkeran) (1 trial)

n803 (12 trials)

necitumumab (portrazza) (1 trial)

nivolumab (opdivo) (2 trials)

nk-92 (24 trials)

omega-3 fatty acids (Omacor) (4 trials)

oxaliplatin (eloxatin) (7 trials)

paclitaxel (taxol) (16 trials)

pd-l1 t-hank (3 trials)

pembrolizumab (keytruda) (2 trials)

ramucirumab (cyramza) (1 trial)

regorafenib (stivarga) (1 trial)

rilotumumab (1 trial)

rituximab (rituxan) (2 trials)

sacituzumab govitecan (Trodelvy) (1 trial)

sorafenib (nexavar) (1 trial)

Drugs in Phase 1 Trials (16)

Key: NantWorks (0) Acquired (16)

abi-011 (1 trial)

allogeneic natural killer cells (1 trial)

bone marrow derived mesenchymal stem cells (1 trial)

cd19 t-hank (2 trials)

cytarabine (cytosar-u) (1 trial)

everolimus (zortress) (1 trial)

fludarabine (fludara) (2 trials)

m-cenk (1 trial)

n-(4-hydroxyphenyl)all-trans retinamide (1 trial)

neukoplast (1 trial)

panitumumab (vectibix) (1 trial)

sargramostim (leukine) (1 trial)

tnx-832 (1 trial)

vrc07-523ls (1 trial)

vrc-hivmab080-00-ab (1 trial)

ye-neo-001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Merkel Cell (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Chordoma (Phase 2)

Colorectal Neoplasms (Phase 2)

Glioblastoma (Phase 1)

Infections (Phase 1)

Leukemia (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 2)

Neuroblastoma (Phase 1)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Clear Cell (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Triple Negative Breast Neoplasms (Phase 2)

Overview

Highest Phase: None
# of Trials: 85
# of Trial APIs: 73